Cyclooxygenase-2: A novel target for cancer chemotherapy?

Wolfram Dempke, Christoph Rie, Axel F Grothey, Hans Joachim Schmoll

Research output: Contribution to journalArticle

363 Citations (Scopus)

Abstract

Epidemiologic studies have documented a 40-50% reduction in incidence of colorectal cancer in individuals taking nonsteroidal antiinflammatory drugs (NSAIDs). Since NSAIDs are known to inhibit cyclooxygenases (COX-1, COX-2), the basic mechanism of their antitumor effects is conceivably the altered metabolism of arachidonic acid and, subsequently, prostaglandins (PGs). Although COX-2, the inducible isoform, is regularly expressed at low levels in colonic mucosa, its activity increases dramatically following mutation of the APC (adenomatous polyposis coli) gene suggesting that β-catenin/T-cell factor mediated Wnt-signaling activity may regulate COX-2 gene expression. In addition, hypoxic conditions and sodium butyrate exposure may also contribute to COX-2 gene transcription in human cancers. The development of selective COX-2 inhibitors has made it possible to further evaluate the role of COX-2 activity in colorectal carcinogenesis. To date, at least five mechanisms by which COX-2 contributes to tumorigenesis and the malignant phenotype of tumor cells have been identified, including: (1) inhibition of apoptosis; (2) increased angiogenesis; (3) increased invasiveness; (4) modulation of inflammation/immuno-suppression; and (5) conversion of procarcinogens to carcinogens. A clear positive correlation between COX-2 expression and inhibition of apoptosis has been established, associated with increased PGE2 levels resulting in modulation of pro- and anti-apoptotic factors (e.g., bcl2, MAKs/ras, caspase-3, Par-4). In terms angiogenesis and invasiveness, COX-2 activity was found to increase the expression of growth factors (e.g., VDEG, PDGF, bFGF) and matrix metalloproteinases (MMPs). Since COX-2 inhibitors have been demonstrated to interfere with tumorigenesis and apoptosis, COX-2 and its gene product may be attractive targets for therapeutic and chemoprotective strategies in colorectal cancer patients. This may lead to new perspectives that by controlling the cancer phenotype, rather than attempting to eradicate all affected cells, may provide significant benefits to the cancer patient.

Original languageEnglish (US)
Pages (from-to)411-417
Number of pages7
JournalJournal of Cancer Research and Clinical Oncology
Volume127
Issue number7
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Cyclooxygenase 2
Drug Therapy
Carcinogenesis
Cyclooxygenase 2 Inhibitors
Apoptosis
Colorectal Neoplasms
Neoplasms
Anti-Inflammatory Agents
APC Genes
TCF Transcription Factors
Phenotype
Catenins
Cyclooxygenase 1
Butyric Acid
Matrix Metalloproteinases
Dinoprostone
Arachidonic Acid
Caspase 3
Pharmaceutical Preparations
Carcinogens

Keywords

  • Biochemistry
  • Carcinogenesis
  • Cyclooxygenase-2
  • Molecular biology

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cyclooxygenase-2 : A novel target for cancer chemotherapy? / Dempke, Wolfram; Rie, Christoph; Grothey, Axel F; Schmoll, Hans Joachim.

In: Journal of Cancer Research and Clinical Oncology, Vol. 127, No. 7, 2001, p. 411-417.

Research output: Contribution to journalArticle

Dempke, Wolfram ; Rie, Christoph ; Grothey, Axel F ; Schmoll, Hans Joachim. / Cyclooxygenase-2 : A novel target for cancer chemotherapy?. In: Journal of Cancer Research and Clinical Oncology. 2001 ; Vol. 127, No. 7. pp. 411-417.
@article{f6972a5522bf488c9df2566ac217bacf,
title = "Cyclooxygenase-2: A novel target for cancer chemotherapy?",
abstract = "Epidemiologic studies have documented a 40-50{\%} reduction in incidence of colorectal cancer in individuals taking nonsteroidal antiinflammatory drugs (NSAIDs). Since NSAIDs are known to inhibit cyclooxygenases (COX-1, COX-2), the basic mechanism of their antitumor effects is conceivably the altered metabolism of arachidonic acid and, subsequently, prostaglandins (PGs). Although COX-2, the inducible isoform, is regularly expressed at low levels in colonic mucosa, its activity increases dramatically following mutation of the APC (adenomatous polyposis coli) gene suggesting that β-catenin/T-cell factor mediated Wnt-signaling activity may regulate COX-2 gene expression. In addition, hypoxic conditions and sodium butyrate exposure may also contribute to COX-2 gene transcription in human cancers. The development of selective COX-2 inhibitors has made it possible to further evaluate the role of COX-2 activity in colorectal carcinogenesis. To date, at least five mechanisms by which COX-2 contributes to tumorigenesis and the malignant phenotype of tumor cells have been identified, including: (1) inhibition of apoptosis; (2) increased angiogenesis; (3) increased invasiveness; (4) modulation of inflammation/immuno-suppression; and (5) conversion of procarcinogens to carcinogens. A clear positive correlation between COX-2 expression and inhibition of apoptosis has been established, associated with increased PGE2 levels resulting in modulation of pro- and anti-apoptotic factors (e.g., bcl2, MAKs/ras, caspase-3, Par-4). In terms angiogenesis and invasiveness, COX-2 activity was found to increase the expression of growth factors (e.g., VDEG, PDGF, bFGF) and matrix metalloproteinases (MMPs). Since COX-2 inhibitors have been demonstrated to interfere with tumorigenesis and apoptosis, COX-2 and its gene product may be attractive targets for therapeutic and chemoprotective strategies in colorectal cancer patients. This may lead to new perspectives that by controlling the cancer phenotype, rather than attempting to eradicate all affected cells, may provide significant benefits to the cancer patient.",
keywords = "Biochemistry, Carcinogenesis, Cyclooxygenase-2, Molecular biology",
author = "Wolfram Dempke and Christoph Rie and Grothey, {Axel F} and Schmoll, {Hans Joachim}",
year = "2001",
doi = "10.1007/s004320000225",
language = "English (US)",
volume = "127",
pages = "411--417",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Cyclooxygenase-2

T2 - A novel target for cancer chemotherapy?

AU - Dempke, Wolfram

AU - Rie, Christoph

AU - Grothey, Axel F

AU - Schmoll, Hans Joachim

PY - 2001

Y1 - 2001

N2 - Epidemiologic studies have documented a 40-50% reduction in incidence of colorectal cancer in individuals taking nonsteroidal antiinflammatory drugs (NSAIDs). Since NSAIDs are known to inhibit cyclooxygenases (COX-1, COX-2), the basic mechanism of their antitumor effects is conceivably the altered metabolism of arachidonic acid and, subsequently, prostaglandins (PGs). Although COX-2, the inducible isoform, is regularly expressed at low levels in colonic mucosa, its activity increases dramatically following mutation of the APC (adenomatous polyposis coli) gene suggesting that β-catenin/T-cell factor mediated Wnt-signaling activity may regulate COX-2 gene expression. In addition, hypoxic conditions and sodium butyrate exposure may also contribute to COX-2 gene transcription in human cancers. The development of selective COX-2 inhibitors has made it possible to further evaluate the role of COX-2 activity in colorectal carcinogenesis. To date, at least five mechanisms by which COX-2 contributes to tumorigenesis and the malignant phenotype of tumor cells have been identified, including: (1) inhibition of apoptosis; (2) increased angiogenesis; (3) increased invasiveness; (4) modulation of inflammation/immuno-suppression; and (5) conversion of procarcinogens to carcinogens. A clear positive correlation between COX-2 expression and inhibition of apoptosis has been established, associated with increased PGE2 levels resulting in modulation of pro- and anti-apoptotic factors (e.g., bcl2, MAKs/ras, caspase-3, Par-4). In terms angiogenesis and invasiveness, COX-2 activity was found to increase the expression of growth factors (e.g., VDEG, PDGF, bFGF) and matrix metalloproteinases (MMPs). Since COX-2 inhibitors have been demonstrated to interfere with tumorigenesis and apoptosis, COX-2 and its gene product may be attractive targets for therapeutic and chemoprotective strategies in colorectal cancer patients. This may lead to new perspectives that by controlling the cancer phenotype, rather than attempting to eradicate all affected cells, may provide significant benefits to the cancer patient.

AB - Epidemiologic studies have documented a 40-50% reduction in incidence of colorectal cancer in individuals taking nonsteroidal antiinflammatory drugs (NSAIDs). Since NSAIDs are known to inhibit cyclooxygenases (COX-1, COX-2), the basic mechanism of their antitumor effects is conceivably the altered metabolism of arachidonic acid and, subsequently, prostaglandins (PGs). Although COX-2, the inducible isoform, is regularly expressed at low levels in colonic mucosa, its activity increases dramatically following mutation of the APC (adenomatous polyposis coli) gene suggesting that β-catenin/T-cell factor mediated Wnt-signaling activity may regulate COX-2 gene expression. In addition, hypoxic conditions and sodium butyrate exposure may also contribute to COX-2 gene transcription in human cancers. The development of selective COX-2 inhibitors has made it possible to further evaluate the role of COX-2 activity in colorectal carcinogenesis. To date, at least five mechanisms by which COX-2 contributes to tumorigenesis and the malignant phenotype of tumor cells have been identified, including: (1) inhibition of apoptosis; (2) increased angiogenesis; (3) increased invasiveness; (4) modulation of inflammation/immuno-suppression; and (5) conversion of procarcinogens to carcinogens. A clear positive correlation between COX-2 expression and inhibition of apoptosis has been established, associated with increased PGE2 levels resulting in modulation of pro- and anti-apoptotic factors (e.g., bcl2, MAKs/ras, caspase-3, Par-4). In terms angiogenesis and invasiveness, COX-2 activity was found to increase the expression of growth factors (e.g., VDEG, PDGF, bFGF) and matrix metalloproteinases (MMPs). Since COX-2 inhibitors have been demonstrated to interfere with tumorigenesis and apoptosis, COX-2 and its gene product may be attractive targets for therapeutic and chemoprotective strategies in colorectal cancer patients. This may lead to new perspectives that by controlling the cancer phenotype, rather than attempting to eradicate all affected cells, may provide significant benefits to the cancer patient.

KW - Biochemistry

KW - Carcinogenesis

KW - Cyclooxygenase-2

KW - Molecular biology

UR - http://www.scopus.com/inward/record.url?scp=0034994651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034994651&partnerID=8YFLogxK

U2 - 10.1007/s004320000225

DO - 10.1007/s004320000225

M3 - Article

C2 - 11469677

AN - SCOPUS:0034994651

VL - 127

SP - 411

EP - 417

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 7

ER -